en · de · es · fr · pt
nad-notes.peptides4088.com › Wiki › Selank Background And Chemical Identity — Explained

Selank Background And Chemical Identity — Explained

By Editorial Desk · published 2025-11-16 · last reviewed 2026-01-08 · Wiki

If you have been reading about GABA-A receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-01-08. Where a claim depends on a specific study, the study is described rather than over-claimed.

Selank Background And Chemical Identity

Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.

Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.

The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.

Mechanism and Evidence Status

Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.

Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.

Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.

Selank at a glance

PropertyValueNotes
Molecular classSynthetic heptapeptideStabilized analog of tuftsin
SequenceThr-Lys-Pro-Arg-Pro-Gly-ProSingle-letter form: TKPRPGP
Molecular formulaC33H57N11O9Monoisotopic mass about 751.9 Da
AppearanceWhite to off-white powderTypically supplied as lyophilized solid
SolubilityFreely soluble in waterAlso soluble in common polar solvents

Origins and Proposed Mechanisms

Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.

Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.

Related pages on this site

Background and Peptide Identity

Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.

Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.

Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.

Analytical Methods and Stability

Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.

Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.

Analytical Methods and Material Handling

Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.

Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.

Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.

Background from the literature

The atherosclerotic process is not well understood. Atherosclerosis is associated with inflammatory processes in the endothelial cells of the vessel wall associated with retained low-density lipoprotein (LDL) particles. This retention may be a cause, an effect, or both of the underlying inflammatory process. The presence of the plaque induces the muscle cells of the blood vessel to stretch, compensating for the additional bulk. The endothelial lining then thickens, increasing the separation between the plaque and the lumen. The thickening somewhat offsets the narrowing caused by the plaque's growth. Moreover, it causes the wall to stiffen and become less compliant to stretching with each heartbeat.

== Reactivity == As a simple, abundant and bifunctional compound, pyruvic acid has been shown to participate in many reactions. Pyruvate reacts with amino acids to give alanine by the process called transamination:

=== Punic Wars === Between 264 and 251 BCE the First Punic War was fought in Sicily, between Rome and Carthage, which ended with the creation of the Roman province of Sicily. Following the Carthaginian provocation with the siege of Saguntum, Spain, the Second Punic War broke out in 217 BCE. The Carthaginian general Hannibal, after taking Saguntum and Marseille, crossed the Alps and defeated the Romans at the Trebbia River, the Ticino River, Lake Trasimeno, and in 216 BCE at Cannae, in Apulia. After the victory at Cannae, Hannibal achieved his first important political-strategic result. He made a brief raid on the Roman Ager before retiring to Capua. Hannibal sent his brother Mago with part of his forces into Bruttium to accommodate the surrender of cities that abandoned the Romans and to force out the rest. The people of Petelia, who remained loyal to the Romans, were attacked by the occupying Carthaginians and by the Bruttians who had allied with Hannibal. After an 11-month siege. Because the Romans were unable to help them, with Roman consent, they surrendered. Hannibal led his army to Cosenza, which, after a less harsh defense, fell to the Carthaginians. An army of Bruttians besieged and occupied another Greek city, Croton, except for the fortress, which was inhabited by less than 2,000 people. The Locrians passed to the Bruttians and the Carthaginians. Only the Regginians preserved their loyalty to Rome and their independence.

== Further reading == Underwood, C.R.; Garibay, P.; Knudsen, L.B.; Peters, G.H.; Rudolph, R. & Reedtz-Runge, S. (January 2010). "Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor". J. Biol. Chem. 285 (1): 723–730. doi:10.1074/jbc.M109.033829. PMC 2804221. PMID 19861722.{{cite journal}}: CS1 maint: multiple names: authors list (link) Nielsen, Malene Løvig (18 December 2015). "Pharmaceutical Researcher is New Honorary Professor at Health". AU.dk. Retrieved 13 May 2024. Lotte Bjerre Knudsen from Novo Nordisk is a new honorary professor at Health, Aarhus University. She is the person behind the discovery of liraglutide, a new class of drugs for Novo Nordisk that are used in the treatment of type 2 diabetes and obesity.

Chronic poisoning is long-term repeated or continuous exposure to a poison where symptoms do not occur immediately or after each exposure. The person gradually becomes ill, or becomes ill after a long latent period. Chronic poisoning most commonly occurs following exposure to poisons that bioaccumulate, or are biomagnified, such as mercury, gadolinium, and lead.

Sources: en.wikipedia.org

Reference notes

The most recognizable contributions of the Stalinist period may be the so-called Seven Sisters, seven large skyscrapers distributed around the city at approximately equal distances from the Kremlin. A defining feature of Moscow's skyline, their imposing form was allegedly inspired by the Manhattan Municipal Building in New York City; their style—with intricate exteriors and a large central spire—has been described as Stalinist Gothic architecture. All seven towers can be seen from most elevated locations in the city. These towers are among the tallest constructions in central Moscow apart from the Ostankino Tower; when this tower was completed in 1967, it was the highest freestanding land structure in the world. It remains the world's seventy-second tallest, ranked among buildings such as the Burj Khalifa in Dubai, Taipei 101 in Taiwan, and the CN Tower in Toronto. The Soviet goal of providing housing for every family, along with the rapid growth of Moscow's population, led to the construction of large, monotonous housing blocks. Most of these were built after Stalin's era, and their styles are often named after the contemporary leader (e.g., Brezhnev and Khrushchev). These blocks are usually badly maintained. Although the city retains some five-story apartment buildings constructed before the mid-1960s, more recent apartment buildings are usually at least nine stories tall and have elevators. Moscow is estimated to have more than twice as many elevators as New York City and four times as many as Chicago.

== Health research == Besides dietary antioxidants, the term has also been applied to various compounds that exhibit antioxidant properties in vitro, having little evidence for antioxidant properties in vivo. Dietary supplements marketed as antioxidants have not been shown to maintain health or prevent disease in humans.

==== MeSH E05.200.875 – microbiological techniques ==== MeSH E05.200.875.150 – bacteriological techniques MeSH E05.200.875.150.125 – bacterial typing techniques MeSH E05.200.875.150.125.150 – bacteriophage typing MeSH E05.200.875.150.125.765 – ribotyping MeSH E05.200.875.150.125.890 – serotyping MeSH E05.200.875.150.570 – limulus test MeSH E05.200.875.220 – colony count, microbial MeSH E05.200.875.595 – microbial sensitivity tests MeSH E05.200.875.595.800 – serum bactericidal test MeSH E05.200.875.610 – mycological typing techniques MeSH E05.200.875.837 – serial passage MeSH E05.200.875.950 – viral load MeSH E05.200.875.970 – virus cultivation MeSH E05.200.875.970.790 – plaque assay MeSH E05.200.875.977 – virus inactivation MeSH E05.200.875.985 – xenodiagnosis

== History == Vancomycin was first isolated in 1953 by a research team led by chemist Edmund Kornfeld at Eli Lilly, from a soil sample provided by missionary William M. Bouw. The sample had been collected in 1952 within a forest on the island of Borneo, after Bouw took over collection duties from the Reverend William W. Conley, who had been a regular contributor to Lilly's global soil screening program since 1948. This program used a network of Christian and Missionary Alliance members to obtain specimens from remote locations to identify novel microorganisms. The organism within the soil that produced the antibiotic was a previously unknown streptomycete originally named Streptomyces orientalis (later reclassified as Amycolatopsis orientalis). Initially designated as "compound 05865", the substance was identified as a distinct antibiotic on June 18, 1953, when researcher Marvin Hoehn used paper chromatography to establish its unique "fingerprint." Unlike many contemporaneous samples that resulted in the rediscovery of known agents like chloromycetin, 05865 exhibited a novel chromatographic pattern and was found to be water-soluble. One of the most difficult tasks Kornfeld's team faced was purification. The early purification method employed during that time utilized picric acid (a potentially explosive chemical); because of this, an alternate process was developed. However, this new method yielded material with a purity of only 82% and, when solubilized, produced a brown liquid termed "Mississippi mud".

Inhibition of these transporters leads to an increase in serotonergic and noradrenergic signalling at postsynaptic receptors. Each drug blocks SERT versus NET differently, which is why there are differences in side effect profiles and therapeutic effects.

Sources: en.wikipedia.org

Frequently asked questions

What is Selank?

Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.

Where was Selank developed?

It was developed in Russia, at the Institute of Molecular Genetics of the Russian Academy of Sciences, during the 1990s. Most published research originates from Russian institutions. Independent international replication remains limited.

How does Selank differ from tuftsin?

Tuftsin is a natural tetrapeptide with the sequence Thr-Lys-Pro-Arg that participates in immune signaling. Selank extends that sequence with Pro-Gly-Pro at the C-terminus. The added residues are linked to greater resistance to enzymatic breakdown.

What mechanisms are proposed for Selank?

Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.

Network